Unlock reliable, efficient, and guideline-compliant Lipoprotein (a) testing
Optimize the accuracy and reporting of your Lipoprotein (a) testing
Three of the guideline recommendations for evaluating increased risk of an Atherosclerotic Cardiovascular Disease1-7 are important when it comes to Lipoprotein (a) [Lp(a)] testing in the laboratory:
- Results should be reported in molar units (nmol/L)
- Mass units (typically mg/L) should not be converted to molar units (typically nmol/L)
- Lp(a) assay should be traceable to internationally recognized IFCC reference material (WHO/IFCC-SRM 2B)
Why choose the Optilite Lp(a) assay?
Accurate results in molar units (nmol/L)
The Optilite Lp(a) assay reports Lp(a) concentrations in nmol/L reflecting the actual particle count. This is crucial for aiding assessment of cardiovascular risk. Since Lp(a) is a complex lipoprotein particle, the biological effects of Lp(a) are related to the particle number rather than the particle mass.
Avoid conversion errors
Converting Lp(a) concentrations can introduce errors due to isoform variability. The Optilite Lp(a) assay ensures you get accurate measurements without the need for conversion.
Traceability to an international standard
The Optilite Lp(a) assay is traceable to the internationally recognized IFCC reference material (WHO/IFCC-SRM 2B).
This ensures measurement accuracy and comparability, providing reliable results which support clinicians when making decisions.
Discover guideline compliance and testing benefits with the Optilite Lp(a) assay
Why does accuracy matter when measuring Lp(a)?
Assays measuring Lp(a) in mass units (mg/L) can introduce size-related bias. This bias may lead to underestimation or overestimation of Lp(a) levels. Such variation depends on the apolipoprotein (a) [apo(a)] isoforms. These isoforms vary due to the number of KIV2 repeats8,9.
The Optilite Lp(a) assay counters this by specifically targeting the KIV9 region, present as a single domain. This is unaffected by particle size variability and apo(a) isoform heterogeneity.
Meet your Lp(a) test demands and more
In addition to the Optilite Lp(a) assay benefits which include accuracy and guideline compliance. Laboratories running the Optilite Lp(a) assay will also benefit from the convenience of the Optilite Analyser:
- Wide Measuring Range: Accurately report results from 3.38 to 440 nmol/L
- Fully Automated to End Result: No manual offline dilutions required
- Superior Quality: Disposable cuvettes eliminate additional wash cycles in the assay protocol. The cuvettes also prevent fogging leading to optic errors.
- Cost Efficiency: Benefit from cost-effective reagent management with up to 3 months open vial stability and 30 days onboard stability
- Enhanced Productivity: Continuous sample loading removes the need for batch loading
The Optilite Lp(a) test ensures peace of mind by delivering results that meet three key guideline recommendations, with the ease and automation from the Optilite Analyser.
Supported by our global teams of technical and scientific experts.
Transform your diagnostic testing with the Optilite Analyser
Cardiovascular disorders assay menu
Laboratories can enhance their efficiency by consolidating tests from the Cardiovascular Disorders Assay Panel. Utilizing a dedicated system specifically designed for specialized protein assays ensures reliable and streamlined operations. This approach allows multiple analyses to be performed from a single serum or plasma tube.
| Description | Product Code | Kit Size | Sample Types |
|---|---|---|---|
| Optilite Lipoprotein (a) Reagent* | LK098.OPT | 100 tests |
Serum and plasma (Li-Hep and EDTA) |
| Optilite Apolipoprotein A-1 Reagent* | NK085.OPT | 100 tests | Serum and plasma (citrate) |
| Optilite Apolipoprotein B Reagent* | NK086.OPT | 100 tests | Serum and plasma (citrate) |
| Optilite High Sensitivity C-reactive Protein Kit | LK044.L.OPT | 100 tests | Serum and plasma (Li-Hep and EDTA) |
*calibrators and controls sold seperately
Product availability is subject to specific regulatory requirements. Contact your local representative for availability in your country.
Optilite is a registered trademark of the Binding Site Group Ltd (Birmingham, UK) in certain countries. Other Brand or product names may be trademarks of their respective holders
References
- Kronenberg et al. European Heart Journal (2022) 43: 3925-3946
- Koschinsky et al. Journal of Clinical Lipidology (2024) 18(3): 308-319
- Celga et al. Atherosclerosis (2019) 291: 62-70
- Durlach et al. Arch Cardiovasc Dis (2021) 114(12): 828-847
- Ward et al. Heart, Lung and Circulation (2023) 32: 287-296
- Li et al. JACC:ASIA (2022) 2(6): 653-665
- Dati et al. CCLM 2004, 6: 670-676
- Marcovina et al. Clin Chem 2003, 49:11:1785–1796
- Marcovina et al. Clin Chem 2000, 46:12:1956-67